PRG-1801

Phase 1Biologic

TTongji Hospital

PRG-1801 is one of 70 biologic programs targeting Immune Thrombocytopenia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune ThrombocytopeniaActive, not recruiting

Lupus NephritisActive, not recruiting

Immune ThrombocytopeniaPhase 1

Active, not recruiting

Lupus NephritisPhase 1

Active, not recruiting

Competition

Competitive Landscape

154 competitors in Lupus Nephritis

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

7 2

Gazyva

Roche

Phase 3

3 3

Myfortic

Novartis

Phase 3

2 4

Saphnelo

AstraZeneca

Phase 3

2 5

Orencia

Bristol-Myers Squibb

Phase 3

2 6

Cosentyx

Novartis

Phase 3

2 7

Arava

Sanofi

Phase 3

2 8

Rayos

RRoxane Laboratories

Phase 3

11 9

Keytruda

Merck & Co.

Phase 3

1 10

Cellcept

Novartis

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Immune Thrombocytopenia

NCT06519565

Q3 2028

Phase 1Recruiting

Lupus Nephritis

NCT06497387

Clinical

Trials by Indication[1]

Lupus Nephritis1 trial

Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease

Recruiting·TTongji Hospital·Phase 1·NCT06497387·30 enrolled

Immune Thrombocytopenia1 trial

Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1·NCT06519565·6 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PRG-1801. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PRG-1801 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PRG-1801. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tongji Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: TTongji Hospital

PRG-1801

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q3 2028

Trials by Indication[1]

Lupus Nephritis1 trial

Immune Thrombocytopenia1 trial

References

Drug Info

Quick Facts

Related News